natgillin/translations-raw huggingface dataset:
In studies performed in rats and rabbits no clinically relevant evidence of harmful effects with respect to pregnancy, embryonal/ foetal development, parturition or postnatal development was observed. 
V študijah na podganah in kuncih niso opazili klinično pomembnih znakov škodljivih učinkov, kar zadeva brejost, razvoj zarodka in ploda, skotitev ali postnatalni razvoj.
An increased relative risk of thromboembolic events (RR 1.67, 95% CI: 1.35, 2.06, 35 trials and 6769 patients) was observed in patients treated with recombinant human erythropoietin. 
Pri bolnikih, zdravljenih z rekombinantnim humanim eritropoetinom, so ugotovili večje relativno tveganje za trombembolične dogodke (RT 1,67, 95 % IZ: 1,35, 2,06; 35 preskušanj in 6769 bolnikov).
• Shortness of breath (dyspnoea) 
• Težko dihanje (dispneja)
• shortened overall survival and increased deaths attributed to disease progression at 4 months in patients with metastatic breast cancer receiving chemotherapy when administered to target a haemoglobin of 12-14 g/dl (7.5-8.7 mmol/l) 
• skrajšala celotno preživetje in povečala število smrti, ki jih je bilo mogoče pripisati napredovanju bolezni po 4 mesecih, pri bolnicah z metastatskim rakom dojke, zdravljenih s kemoterapijo, če je bila ciljna vrednost hemoglobina od 120 do 140 g/l (od 7,5 do 8,7 mmol/l).
Do not touch this area again before giving the injection. 
Tega mesta se potem pred injiciranjem ne smete več dotakniti.
Press the pre-filled pen onto the skin to unlock the safety guard. 
Pritisnite napolnjeni injekcijski peresnik na kožo, da boste sprostili varnostno zaščito.
Keep the container in the outer carton, in order to protect from light. 
Vsebnik shranjujte v zunanji ovojnini za zagotovitev zaščite pred svetlobo.
Very rare (seen in less than 1 in 10,000 people) 
Zelo redki (pojavijo se pri manj kot 1 od 10.000 oseb)
For pediatric patients 1-18 years of age, clinical data in paediatric patients has demonstrated that patients receiving r-HuEPO two or three times weekly may be converted to once weekly Nespo, and those receiving r-HuEPO once weekly may be converted to once every other week Nespo. 
Za pediatrične bolnike od 1. do 18. leta starosti klinični podatki pri pediatričnih bolnikih kažejo, da lahko tisti, ki dobivajo r-HuEPO dva- ali trikrat na teden, preidejo na Nespo enkrat na teden, tisti, ki dobivajo r-HuEPO enkrat na teden, pa na Nespo enkrat vsak drugi teden.
Solution for injection (injection) in a vial. 
Raztopina za injiciranje (injekcija) v viali.
Nespo (SureClick) is available in packs containing 1 or 4 pre-filled pens (not all pack sizes may be marketed). 
Nespo (SureClick) je na voljo v pakiranjih, ki vsebujejo 1 ali 4 napolnjene injekcijske peresnike (na trgu lahko ni vseh navedenih pakiranj).
Nespo is given as a single injection, either once a week or once every three weeks, under your skin. 
Nespo vbrizgamo v eni injekciji, bodisi enkrat na teden, ali enkrat na tri tedne, in sicer pod kožo
Keep unlocked against skin 
• Izpuščaj na koži
If you have any further questions, ask your doctor, nurse or pharmacist. 
Če imate dodatna vprašanja, se posvetujte z zdravnikom, medicinsko sestro ali farmacevtom.
• Allergic reactions, including anaphylactic reaction, angioedema, skin rash and urticaria. 
• Alergijske reakcije, vključno z anafilaktično reakcijo, angioedemom, izpuščajem in urtikarijo.
If someone else is giving you the injection, they can also use the outer area of the upper arms. 
Če vam zdravilo injicira kdo drug, vam ga lahko da tudi v zunanjo stran nadlakta.
Do not use Nespo after the expiry date which is stated on the carton and on the pre-filled pen label after EXP. 
Zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in nalepki napolnjenega injekcijskega peresnika z oznako "Upor.
In order to correct your anaemia, your initial dose will be • 500 micrograms once every three weeks (6.75 micrograms of Nespo per kilogram of your body 
Za odpravljanje anemije boste dobili začetni odmerek • 500 mikrogramov enkrat na tri tedne (6,75 mikrogramov Nespa na kilogram telesne mase enkrat
If your doctor has decided to change your treatment from r-HuEPO (erythropoietin produced by genetechnology) to Nespo, they will choose whether you should receive your Nespo injection once weekly or once every two weeks. 
Če se zdravnik odloči, da vam namesto zdravljenja z r-HuEPO (genskotehnološko pridobljenega eritropoetina) predpiše Nespo, bo tudi določil, ali morate injekcijo Nespa dobiti enkrat na teden ali enkrat na dva tedna.
In a prospective, randomised double-blind, placebo-controlled study conducted in 314 lung cancer patients receiving platinum containing chemotherapy there was a significant reduction in transfusion requirements (p < 0.001). 
V prospektivni, randomizirani, dvojno slepi, s placebom kontrolirani študiji pri 314 bolnikih z rakom na pljučih, ki so dobivali kemoterapijo s platino, so ugotovili značilno zmanjšanje potreb po transfuziji
The carcinogenic potential of darbepoetin alfa has not been evaluated in long-term animal studies. 
Kancerogenega potenciala darbepoetina alfa niso ocenili v
DO NOT use Nespo: 
Ne uporabite Nespa, če
Non-response to therapy with Nespo should prompt a search for causative factors. 
Če se bolnik na terapijo z Nespom ne odzove, je treba raziskati vzročne dejavnike za to.
Nespo should be used with caution in patients with epilepsy. 
Pri bolnikih z epilepsijo morate Nespo uporabljati previdno.
As there is no clinical experience with lactating women Nespo should not be administered to women who are breast-feeding. 
Kliničnih izkušenj z Nespom pri doječih ženskah ni, zato ga pri takšnih ženskah ne smete uporabljati.
• Misuse by healthy people can cause life-threatening problems with the heart or blood vessels. 
• Če zdravstveni delavci zdravilo uporabijo nepravilno, se lahko pojavijo smrtno nevarne težave na srcu ali ožilju.
The Nespo pre-filled pen is given as a single injection, either once a week, once every two weeks, or once every month. 
Nespo v napolnjenem injekcijskem peresniku vbrizgamo kot eno injekcijo, bodisi enkrat na teden, enkrat na dva tedna ali enkrat na mesec.
If you feel unwell in any way you should contact your doctor, nurse or pharmacist immediately. 
Če se počutite kakorkoli slabo, se takoj posvetujte z zdravnikom, medicinsko sestro ali farmacevtom.
Haemoglobin variability should be addressed through dose management, with consideration for the haemoglobin target range of 10 g/dl (6.2 mmol/l) to 12 g/dl (7.5 mmol/l). 
Variabilnosti hemoglobina se je treba prilagoditi z uravnavanjem odmerka, pri čemer je treba upoštevati ciljno območje koncentracije hemoglobina od 100 g/l (6,2 mmol/l) do 120 g/l (7,5 mmol/l).
• an allergy to latex (the needle cover on the pre-filled syinge contains a derivative of latex). 
• alergijo na lateks (pokrovček igle na napolnjenem injekcijskem peresniku vsebuje snov, pridobljeno iz lateksa).
• Hives (urticaria) 
• Urtikarija (koprivnica)
Rotate the injection sites and inject slowly to avoid discomfort at the site of injection. 
Mesto injiciranja krožno menjajte, zdravilo pa injicirajte počasi, da se boste izognili neprijetnemu
For the abdomen, it is recommended to lie down on your back, and stretch the skin at the injection site to create a firm and 
Če boste injicirali v trebuh, je najbolje, da se uležete na hrbet in raztegnete kožo na mestu injiciranja, tako da ustvarite čvrsto in napeto površino.
FRONT- Nespo getting started guide: 
SPREDNJA STRAN - Navodilo za začetek uporabe Nespoa:
• convulsions (fits or seizures); 
• konvulzije (napade krčev),
Erythropoetin is a growth factor that primarily stimulates red blood cell production. 
Eritropoetini so rastni dejavniki, ki spodbujajo predvsem nastajanje rdečih krvnih celic.
- Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached - At the request of the EMEA 
farmakovigilančni načrt ali na dejavnosti za zmanjšanje tveganja; - v 60 dneh, potem ko je dosežen pomemben mejnik (pri farmakovigilanci ali zmanjšanju tveganja);
How do you or the person injecting you, use the Nespo pre-filled syringe? 
Kako naj vi sami ali oseba, ki vam injicira zdravilo, uporabite napolnjeno injekcijsko brizgo
Your doctor has decided that the Nespo pre-filled pen is the best way for you, a nurse, or a carer to inject Nespo. 
Zdravnik je uporabo napolnjenega injekcijskega peresnika Nespo ocenil kot najboljši način, da si zdravilo injicirate sami, da vam ga injicira medicinska sestra ali oseba, ki skrbi za vas.
Check the appearance of Nespo through the inspection window. 
Skozi okence preverite videz Nespa.
If the inspection window is not yellow, you must contact your doctor, nurse or pharmacist. 
Če okence ni rumeno, se obrnite na zdravnika, medicinsko sestro ali
Marketing Authorisation Holder: Dompé Biotec S.p.A. 
Imetnik dovoljenja za promet z zdravilom: Dompé Biotec S.p.A.
The active substance of Nespo is darbepoetin alfa produced by gene-technology in Chinese Hamster Ovary Cells (CHO-K1). 
Zdravilna učinkovina v zdravilu Nespa je darbepoetin alfa, pridobljen z gensko tehnologijo v ovarijskih celicah kitajskega hrčka (CHO-K1).
The initial weekly dose of Nespo (µg/week) can be determined by dividing the total weekly dose of r-HuEPO (IU/week) by 200. 
Začetni tedenski odmerek Nespa (µg/teden) lahko določite tako, da celotni tedenski odmerek r-HuEPO (i.e./teden) delite z 200.
OTHER Dompé Biotec S.p.A. 
DRUGI PODATKI Dompé Biotec S.p.A.
When substituting Nespo for r-HuEPO the haemoglobin should be monitored every one or two weeks and the same route of administration should be used. 
Pri zamenjavi r-HuEPO z Nespom je treba uporabiti isto pot aplikacije, hemoglobin pa kontrolirati na en do dva tedna.
In clinical studies, an increased risk of death, serious cardiovascular events, and vascular access thrombosis was observed when erythropoiesis-stimulating agents (ESAs) were administered to target a haemoglobin of greater than 12 g/dl (7.5 mmol/l). 
V kliničnih študijah so ugotovili večje tveganje smrti, resnih srčnožilnih dogodkov, in tromboze na žilnem dostopu kadar so eritropoezo stimulirajoče agense (ESA) uporabljali tako, da je bil ciljni hemoglobin nad 120 g/l (7,5 mmol/l).
1 single use pre-filled syringe 4 single use pre-filled syringes 
1 napolnjena injekcijska brizga za enkratno uporabo 4 napolnjene injekcijske brizga za enkratno uporabo
The initial weekly or once every other week pediatric dose of Nespo (µg/week) can be determined by dividing the total weekly dose of r-HuEPO (IU/week) by 240. 
Začetni pediatrični odmerek Nespa (µg/teden) enkrat na teden ali enkrat vsak drugi teden lahko določite tako, da celotni tedenski odmerek r-HuEPO (i.e./teden) delite z 240.
Patients should be monitored closely to ensure that the lowest approved dose of Nespo is used to provide adequate control of the symptoms of anaemia. 
Bolnike morate natančno kontrolirati in tako zagotoviti uporabo najmanjšega odobrenega odmerka Nespa, ki je potreben za ustrezno obvladanje simptomov anemije..
In these patients an upper limit of 12 g/dl (7.5 mmol/l) should be aimed for, unless severe symptoms (e.g. angina) dictate otherwise. 
Pri takšnih bolnikih naj bi bila ciljna zgornja meja 120 g/l (7,5 mmol/l), razen če hudi simptomi (npr. angina pektoris) ne narekujejo drugače.
In isolated cases, neutralising anti-erythropoietin antibody mediated pure red cell aplasia (PRCA) associated with Nespo therapy have been reported predominantly in patients with CRF treated subcutaneously. 
V posameznih primerih je bila v povezavi s terapijo z Nespom opisana čista aplazija rdečih celic zaradi nevtralizirajočih protieritropoetinskih protiteles, pretežno pri bolnikih s kronično odpovedjo ledvic, ki so zdravilo dobivali subkutano.
The syringes inside the pen are made from type 1 glass with stainless steel 27 gauge needles. 
Injekcijska brizga v peresniku je iz stekla tipa 1 in ima nerjavno jekleno iglo številka 27.
Do not remove the grey needle cap from the pre-filled pen until you are ready to inject. 
Ne odstranite sivega ščitnika igle z napolnjenega injekcijskega peresnika, dokler niste
• a new Nespo pre-filled syringe; and 
• novo napolnjeno injekcijsko brizgo zdravila Nespo in
Data presented from controlled studies included 1357 patients, 766 who received Nespo and 591 patients who received r-HuEPO. 
Podatki iz kontroliranih študij zajemajo 1357 bolnikov: 766 jih je dobivalo Nespo in 591 r-HuEPO.
Check window to confirm delivery of full dose 
Poglejte okence, da boste preverili, ali je bil injiciran celotni odmerek
You may rotate the site for each injection to avoid soreness at any one site. 
Mesto injiciranja lahko krožno menjate, da boste preprečili bolečine na posameznem mestu.
There may be a little bleeding at the injection site. 
Mesto injiciranja lahko rahlo krvavi.
Check the expiry date on the pre-filled syringe label (EXP:). 
Preverite datum izteka roka uporabnosti na nalepki napolnjene injekcijske brizge (Upor.
Clinical studies have demonstrated that adult patients receiving r-HuEPO one, two or three times weekly may be converted to once weekly or once every other week Nespo. 
Klinične študije so pokazale, da lahko odrasli bolniki, ki dobivajo r-HuEPO enkrat, dvakrat ali trikrat na teden, preidejo na Nespo enkrat na teden ali enkrat na dva tednaNespo.
The initial every other week dose of Nespo (μg/every other week) can be determined by dividing the total cumulative dose of r-HuEPO administered over a two-week period by 200. 
Začetni odmerek Nespa na dva tedna (µg vsak drugi teden) lahko določite tako, da celotni kumulativni odmerek r-HuEPO, apliciran v dveh tednih, delite z 200.
If you have any problems, please do not be afraid to ask your doctor or nurse for help and advice. 
Če imate kakršnekoli težave, brez obotavljanja prosite za pomoč in nasvet zdravnika ali medicinsko sestro.
Nespo is a clear, colourless or slightly pearly liquid. 
Nespo je bistra, brezbarvna ali rahlo biserna tekočina.
The best places to inject yourself arethe top of your thighs andthe abdomen. 
Najprimernejši mesti za samoinjiciranje sta zgornji del stegen in trebuh.
You should have no serious problems if you take more Nespo than you need. 
Če uporabite več Nespa, kot je potrebno, to ne bi smelo povzročiti resnih težav.
There have been reports of serious allergic reactions including anaphylactic reaction, angioedema, dyspnoea, skin rash and urticaria associated with darbepoetin alfa. 
V povezavi z darbepoetinom alfa so bile opisane resne alergijske reakcije, vključno z anafilaktično reakcijo, angioedemom, dispnejo, izpuščajem na koži in urtikarijo.
D Do wait for the injection to finish before releasing pressure. 
D Pritiska ne popustite, dokler se injiciranje ne konča.
The following adverse reactions have been identified during postmarketing use of Nespo: 
Pomarketinške izkušnje Med pomarketinško uporabo Nespa so ugotovili naslednje neželene učinke:
For subcutaneous use Read the package leaflet before use. 
Pred uporabo preberite priloženo navodilo.
The initial dose by subcutaneous or intravenous administration is 0.45 µg/kg body weight, as a single injection once weekly. 
Začetni subkutani ali intravenski odmerek je 0,45 µg/kg telesne mase v eni injekciji enkrat na teden.
Incidence of undesirable effects considered related to treatment with Nespo from controlled clinical studies are: 
Pogostnosti neželenih učinkov, ki veljajo za povezane z Nespom in so jih zabeležili v kontroliranih
PRCA means that the body has stopped or reduced the production of red blood cells which causes severe anaemia. 
Čista aplazija rdečih celic pomeni, da so v telesu nehale nastajati rdeče krvne celice; posledica je huda anemija.
Very Common (seen in more than 10 in 100 people) 
Zelo pogosti (pojavijo se pri več kot 10 od 100 oseb)
Survival and tumour progression have been examined in five large controlled studies involving a total of 2833 patients, of which four were double-blind placebo-controlled studies and one was an openlabel study. 
Preživetje bolnikov in napredovanje tumorja so raziskali v petih velikih kontroliranih študijah, ki so skupaj zajele 2833 bolnikov.
4.7 Effects on ability to drive and use machines 
4.7 Vpliv na sposobnost vožnje in upravljanja s stroji Ni ugotovljeno, da bi Nespa vplival na sposobnost vožnje in upravljanja s stroji.
In patients with solid tumours or lymphoproliferative malignancies, if the haemoglobin value exceeds 12 g/dl (7.5 mmol/l), the dosage adaptation described in section 4.2 should be closely respected, in order to minimise the potential risk of thromboembolic events. 
Če hemoglobin pri bolnikih s čvrstimi tumorji ali limfoproliferativnimi malignomi preseže 120 g/l (7,5 mmol/l), natančno upoštevajte prilagoditev odmerka, opisano v poglavju 4.2, da boste zmanjšali morebitno tveganje za trombembolične incidente.
Alternatively, in patients not on dialysis, an initial dose of 0.75 μg/kg may be administered subcutaneously as a single injection once every two weeks. 
Pri bolnikih, ki niso na dializi, je druga možnost začetni odmerek 0,75 μg/kg subkutano v eni injekciji enkrat na dva tedna.
Nespo also contains sodium phosphate monobasic, sodium phosphate dibasic, sodium chloride, polysorbate 80 and water for injections. 
Nespo vsebuje tudi natrijev hidrogenfosfat, natrijev dihidrogenfosfat, natrijev klorid, polisorbat 80 in vodo za injekcije.
Your doctor may decide that it is best for you or a carer to inject Nespo. 
Zdravnik lahko presodi, da je za vas najbolje, če si Nespo injicirate sami oz. vam ga injicira oseba, ki za vas skrbi.
Nespo should be administered by the subcutaneous route to patients with anaemia (e.g. haemoglobin concentration ≤ 10 g/dl (6.2 mmol/l)) in order to increase haemoglobin to not greater than 12 g/dl (7.5 mmol/l). 
Bolniki z anemijo (npr. koncentracijo hemoglobina ≤ 100 g/l (6,2 mmol/l)) morajo Nespo dobiti subkutano s ciljem, da se hemoglobin zviša na ne več kot 120 g/l (7,5 mmol/l).
Pull slightly on the plunger to check that a blood vessel has not been punctured. 
Nekoliko izvlecite bat; tako se boste prepričali, da niste zabodli v žilo.
Paediatric patients with chronic renal failure 
Pediatrični bolniki s kronično odpovedjo ledvic
METHOD OF ADMINISTRATION EXPIRY DATE 
Datum izteka roka uporabnosti se nanaša
Solution for injection (injection) in a pre-filled syringe. 
Raztopina za injiciranje (injekcija) v napolnjeni injekcijski brizgi.
Treatment of symptomatic chemotherapy induced anaemia in cancer patients 
Zdravljenje simptomatske anemije zaradi kemoterapije pri onkoloških bolnikih
Your doctor will take regular blood samples to measure how your anaemia is responding and may adjust your dose as necessary. 
Zdravnik vam bo redno jemal kri za meritve, ki bodo pokazale, kako dobro se anemija odziva, in bo lahko odmerek prilagodil, kot bo potrebno .
Disposing of used syringes 
Odlaganje rabljenih napolnjenih injekcijskih peresnikov
For patients ≥11 years of age, the initial dose by subcutaneous or intravenous administration is 0.45 µg/kg body weight, as a single injection once weekly. 
Za bolnike, stare ≥ 11 let, je začetni subkutani ali intravenski odmerek 0,45 µg /kg telesne mase v eni injekciji enkrat na teden.
If an elevated or rising potassium level is observed then consideration should be given to ceasing Nespo administration until the level has been corrected. 
Če se izkaže, da je kalij zvišan ali se zvišuje, pride v poštev prenehanje uporabe Nespa, dokler se koncentracija kalija ne uredi.
• shortened time to tumour progression in patients with advanced head and neck cancer receiving radiation therapy when administered to target a haemoglobin of greater than 14 g/dl (8.7 mmol/l), ESAs are not indicated for use in this patient population. 
• skrajšala čas do napredovanja tumorja pri bolnikih z napredovalim rakom glave in vratu, zdravljenih z obsevanjem, če je bila ciljna vrednost hemoglobina več kot 140 g/l (8,7 mmol/l).
Nespo is used to treat symptomatic anaemia that is associated with chronic renal failure (kidney failure) in adults and children. 
Nespo uporabljamo za zdravljenje simptomatske anemije, ki spremlja kronično odpoved ledvic pri odraslih in otrocih.
Serum potassium levels should be monitored regularly during Nespo therapy. 
Med zdravljenjem z Nespom je treba redno kontrolirati koncentracijo kalija v serumu.
Injection site pain 
bolečina na mestu injiciranja
In these patients, erythropoietin deficiency and a reduced response of erythroid progenitor cells to endogenous erythropoietin both contribute significantly towards their anaemia. 
Pri teh bolnikih k anemiji bistveno pripomoreta tako pomanjkanje eritropoetina kot slabši odziv eritroidnih matičnih celic na
Convulsions (fits and seizures) have been reported in patients treated with Nespo. 
Pri bolnikih, zdravljenih z Nespom, so bile opisane konvulzije (napadi krčev).
Keep in the original package in order to protect from light. 
Shranjuje v originalni ovojnini za zagotovitev zaščite pred svetlobo.
• if you are allergic to Nespo (darbepoetin alfa), r-HuEPO or to any of the other ingredients in Take special care with Nespo 
• če ste preobčutljivi za (alergični na) Nespo (darbepoetin alfa), r-HuEPO ali katerokoli sestavino Bodite posebno pozorni pri uporabi zdravila Nespo Zdravniku povejte,če imate ali ste kdaj imeli:
Rare (seen in more than 1 in 10,000 people) 
Redki (pojavijo se pri več kot 1 od 10.000 oseb)
Cancer patients 
Onkološki bolniki
Dialysis patients converting from once weekly to once every other week dosing with Nespo should initially receive a dose equivalent to twice the previous once weekly dose. 
Bolniki na dializi, ki preidejo z uporabe Nespa enkrat na teden na uporabo Nespa enkrat na dva tedna, morajo sprva dobivati odmerek, enak dvojnemu odmerku, ki so ga do tedaj dobivali enkrat na teden.
If you use more Nespo than you should 
Če ste uporabili večji odmerek zdravila Nespo, kot bi smeli
Cyclosporin and tacrolimus may be affected by the number of red cells in your blood. 
Število rdečih celic v krvi lahko vpliva na zdravili ciklosporin in takrolimus.
Nespo is available in packs of 1 or 4 vials (not all pack sizes may be marketed). 
Nespo je na voljo v pakiranjih z 1 ali 4 vialami (na trgu morda ni vseh velikosti pakiranj).
Check the expiry date on the pre-filled pen label (EXP:). 
Preverite datum izteka roka uporabnosti na nalepki napolnjenega injekcijskega peresnika (Upor.
Please read this leaflet carefully before you start using this medicine. 
Pred uporabo natančno preberite navodilo.
In the maintenance phase, Nespo may continue to be administered as a single injection once weekly or once every two weeks. 
Med obdobjem vzdrževanja je mogoče Nespo še naprej uporabljati v eni injekciji na teden ali na dva tedna.
Nespo comes in a vial that contains either 15, 25, 40 or 60 micrograms of the active substance darbepoetin alfa. 
Nespo je na voljo v vialah, ki vsebujejo 15, 25, 40 ali 60 mikrogramov zdravilne učinkovine
Common (seen in more than 1 in 100 people) 
Pogosti (pojavijo se pri več kot 1 od 100 oseb)
Avoid areas with scars or stretch marks. 
Ne injicirajte v predele z brazgotinami ali strijami.
Any medicinal product remaining in the pre-filled syringe should be disposed of. 
Ostanek zdravila v napolnjeni injekcijski brizgi morate zavreči.
Treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy. 
Nespo uporabljamo za zdravljenje simptomatske anemije pri odraslih bolnikih, ki imajo nemieloidnega raka in dobivajo kemoterapijo.
In this leaflet 
ESA v tej populaciji
A rise in haemoglobin of greater than 2 g/dl (1.25 mmol/l) over a four week period should be avoided. 
Izogniti se je treba zvišanju koncentracije hemoglobina, večjemu od 20 g/l (1,25 mmol/l) v štirih tednih.
Excipients: sodium phosphate monobasic, sodium phosphate dibasic, sodium chloride, polysorbate 80, water for injections. 
Pomožne snovi: natrijev hidrogenfosfat, natrijev dihidrogenfosfat, natrijev klorid, polisorbat 80, voda
If the haemoglobin exceeds 12 g/dl (7.5 mmol/l), a dose reduction should be considered. 
Če hemoglobin preseže 120 g/l (7,5 mmol/l), pride v poštev zmanjšanje odmerka.
The syringes are provided either with (1-& 4-pack) or without (1-pack) a blister-wrapping. 
Brizge so opremljene v pretisnih omotih (pakiranje z 1 ali 4) ali brez njih